Todays PR is a reflection of Brilacidin's success as an antiviral. It proves the original thought of the U of Penn researchers who developed Brilacidin as a defensin mimetic.
Paraphrasing Doctor William DeGrado ...billions of possible compounds can be created but only an extremely small percentage of them will prove to be biologically active. Defensins have evolved to have significant biologic activity. We can take advantage of this evolutionary development by strengthening and modifying the core of the defensins to produce pharmaceuticals.
Polymedixs studied hundreds of Defensin mimetics. Brilacidins success has validated the idea and produced more interest in studying these compounds, many of which are controlled by IPIX.
Dr Richard Scott, one of the original Polymedix scientists who developed Brilacidin, is vice President of research at Fox Chase.
Dr. Scott has spent over 28 years in the pharmaceutical industry and has extensive experience in multiple disciplines including microbiology, anti-infectives, acute coronary care, neurobiology and animal model development. He began his career as a Principal Investigator in Central Research Development at E.I. Dupont deNemours and then moved to Cephalon, Inc. in 1991 where he held positions of increasing responsibility prior to becoming Vice President of Neurobiology. He led groups involved in recombinant expression of target gene products, establishment of transgenic and gene-targeted animal models of neurodegenerative disease processes, and drug discovery in signal transduction pathways. In 2002, he co-founded PolyMedix, a company focused on the development non-peptidic mimics of the host defense proteins for infectious disease and cardiovascular disorders. He led the research team responsible for the identification and selection of the clinical lead compound, brilacidin, that successfully completed a Phase 2 clinical study for treatment of acute bacterial skin and skin structure infections (ABSSSI) and identified a potent antagonist of heparin and low molecular weight heparins (delparantag) that also reached Phase 2 clinical study. Additional programs in the research group that were supported by grants from the NIH, NSF and Departments of Defense included the development of antimicrobial mimetics for treatment of Gram-negative infections, oral and disseminated Candidiasis, malaria and food-borne infections. Dr. Scott is an author on over 67 peer-reviewed journal articles and book chapters, and is an inventor on 8 US patents.
News 
Market Data 
Discover 
